Drug Trial Radar · NCT07623525
DIAG723 in Adults With Hereditary Hemorrhagic Telangiectasia
Last checked: Nov 20, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
93
Planned (sponsor's estimate)
Start
Jun 4, 2026
Primary completion
Nov 30, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Diagonal Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2, randomized, double-blind, placebo-controlled, first-in-human study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of subcutaneously administered DIAG723 in adult patients with hereditary hemorrhagic telangiectasia (HHT). The study consists of three parts: Part A (dose escalation): Single ascending subcutaneous doses of DIAG723 are evaluated in sequential cohorts to assess safety, tolerability, and pharmacokinetics. Part B (dose expansion): Multiple doses of DIAG723 administered over 13 weeks are evaluated in patients with HHT to assess safety and preliminary efficacy. Part C (dose expansion): Multiple doses of DIAG723 administered over 13 weeks are evaluated in patients with HHT and concomitant pulmonary arterial hypertension to assess safety and exploratory clinical effects in this population. Participants will be randomized within each study part to receive DIAG723 or placebo. The study includes dose escalation in Part A and dose expansion in Parts B and C.
Conditions
- Hereditary Hemorrhagic Telangiectasia
- Pulmonary Arterial Hypertension
Interventions
DIAG723Biological
Bispecific agonist monoclonal antibody targeting ALK-1 and BMPRII, administered subcutaneously as: Single ascending dose in Part A; Multiple doses (7 doses over 13 weeks) in Parts B and C
PlaceboOther
Sterile normal saline (0.9% NaCl) administered subcutaneously in volumes matched to DIAG723 to maintain study blinding.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse Events (TEAEs) - Part A (Single Dose)Time frame: From first dose through Day 28
- Incidence of Serious Adverse Events (SAEs) - Part A (Single Dose)Time frame: From first dose through Day 28
- Incidence of Dose-Limiting Toxicities (DLTs) - Part A (Single Dose)Time frame: From first dose through Day 28
- Number of participants with abnormal laboratory tests results - Part A (Single Dose)Time frame: Baseline through Day 28
- Number of participants with abnormal vital signs - Part A (Single Dose)Time frame: Baseline through Day 28
- Change from Baseline in Electrocardiogram (ECG) Parameters - Part A (Single Dose)Time frame: Baseline through Day 28
- Incidence of Treatment-Emergent Adverse Events (TEAEs) - Part B (Multiple Dose)Time frame: From first dose through 28 days after final dose
- Incidence of Serious Adverse Events (SAEs) - Part B (Multiple Dose)Time frame: From first dose through 28 days after final dose
- Incidence of Dose-Limiting Toxicities (DLTs) - Part B (Multiple Dose)Time frame: From first dose through 28 days after final dose
- Number of participants with abnormal laboratory tests results - Part B (Multiple Dose)Time frame: Baseline through Week 15
- Number of participants with abnormal vital signs - Part B (Multiple Dose)Time frame: Baseline through Week 17
- Change from Baseline in Electrocardiogram (ECG) Parameters - Part B (Multiple Dose)Time frame: Baseline through Week 17
- Incidence of Treatment-Emergent Adverse Events (TEAEs) - Part C (Multiple Dose, HHT with PAH)Time frame: From first dose through 28 days after final dose
- Incidence of Serious Adverse Events (SAEs) - Part C (Multiple Dose, HHT with PAH)Time frame: From first dose through 28 days after final dose
- Incidence of Dose-Limiting Toxicities (DLTs) - Part C (Multiple Dose, HHT with PAH)Time frame: From first dose through 28 days after final dose
- Number of participants with abnormal laboratory tests results - Part C (Multiple Dose, HHT with PAH)Time frame: Baseline through Week 15
- Number of participants with abnormal vital signs - Part C (Multiple Dose, HHT with PAH)Time frame: Baseline through Week 17
- Change from Baseline in Electrocardiogram (ECG) Parameters - Part C (Multiple Dose, HHT with PAH)Time frame: Baseline through Week 17
Locations
11 sites in 3 countries. Site status is shown where the registry gives one.
Diagonal Investigational Site
Camperdown, New South Wales, Australia · Not yet recruiting
Diagonal Investigational Site
Randwick, New South Wales, Australia · Recruiting
Diagonal Investigational Site
Herston, Queensland, Australia · Not yet recruiting
Diagonal Investigational Site
Herston, Queensland, Australia · Withdrawn
Diagonal Investigational Site
East Melbourne, Victoria, Australia · Recruiting
Diagonal Investigational Site
Parkville, Victoria, Australia · Not yet recruiting
Diagonal Investigational Site
West Perth, Western Australia, Australia · Not yet recruiting
Diagonal Investigational Site
Toronto, Ontario, Canada · Not yet recruiting
Diagonal Investigational Site
Toronto, Ontario, Canada · Not yet recruiting
Diagonal Investigational Site
Laval, Quebec, Canada · Not yet recruiting
Diagonal Investigational Site
Grafton, Auckland, New Zealand · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.